Abbott Laboratories (NYSE:ABT) on Thursday posted upbeat first-quarter earnings but revised its 2026 earnings outlook below expectations.
The global healthcare company reported quarterly sales of $11.16 billion, slightly beating the consensus of $10.99 billion. Abbott reported adjusted earnings of $1.15 per share, beating the Wall Street estimate of $1.14 and management guidance of $1.12-$1.18 per share.
The global healthcare company on Thursday said it expects the second quarter of 2026 adjusted earnings of $1.25-$1.31, below the consensus of $1.37. Abbott lowered its fiscal 2026 adjusted earnings from $5.55-$5.80 per share to $5.38-$5.58 per share compared to the Wall Street consensus of $5.62.
The updated guidance includes 20 cents per share of dilution related to the acquisition of Exact Sciences. The company projects fiscal 2026 comparable sales growth of 6.5% to 7.5%.
Robert Ford, Chairman and CEO of Abbott, said, "We forecast the addition of Exact Sciences to add approximately $3 billion of incremental sales in 2026 and accelerate Abbott's long-term sales growth rate."
Abbott shares slipped 0.1% to close at $95.47 on Thursday.
These analysts made changes to their price targets on Abbott following earnings announcement.
- Stifel analyst Rick Wise maintained Abbott with a Buy and lowered the price target from $145 to $120.
- B of A Securities analyst Travis Steed maintained the stock with a Buy and lowered the price target from $150 to $120.
- Evercore ISI Group analyst Vijay Kumar maintained Abbott with an Outperform rating and cut the price target from $134 to $120.
- Benchmark analyst Bruce D. Jackson maintained the stock with a Buy and lowered the price target from $145 to $120.
Considering buying ABT stock? Here’s what analysts think:
Photo via Shutterstock
Comments